Arcus Biosciences, Inc. Non Peo Neo Avg Total Comp Amt
Arcus Biosciences, Inc. (RCUS) reported Non Peo Neo Avg Total Comp Amt of $3.55 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-21.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-21
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $3.55M DEF 14A · filed 2026-04-21 |
| 2024-12-31 | $2.79M DEF 14A · filed 2026-04-21 |
| 2023-12-31 | $4.19M DEF 14A · filed 2026-04-21 |
| 2022-12-31 | $4.19M DEF 14A · filed 2026-04-21 |
| 2021-12-31 | $5.94M DEF 14A · filed 2026-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |